fluoxetine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 6 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has antidepressant and antiparkinsonian potential due to anti-inflammatory neurogenic, and neuroplasticity-inducing effects when combined with fluoxetine." | 1.72 | Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. ( Costa, BLDSAD; Duarte-Silva, EP; Melo, MG; Mendonça, IP; Oliveira, WH; Paiva, IHR; Peixoto, CA; Silva, RSD, 2022) |
| " In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats." | 1.42 | Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mendonça, IP | 1 |
| Paiva, IHR | 1 |
| Duarte-Silva, EP | 1 |
| Melo, MG | 1 |
| Silva, RSD | 1 |
| Oliveira, WH | 1 |
| Costa, BLDSAD | 1 |
| Peixoto, CA | 1 |
| Sharifi, H | 1 |
| Nayebi, AM | 1 |
| Farajnia, S | 1 |
| Haddadi, R | 1 |
| Chung, ES | 1 |
| Chung, YC | 1 |
| Bok, E | 1 |
| Baik, HH | 1 |
| Park, ES | 1 |
| Park, JY | 1 |
| Yoon, SH | 1 |
| Jin, BK | 1 |
| Saddichha, S | 1 |
| Kumar, R | 1 |
| Babu, GN | 1 |
| Chandra, P | 1 |
| Bishop, C | 1 |
| George, JA | 1 |
| Buchta, W | 1 |
| Goldenberg, AA | 1 |
| Mohamed, M | 1 |
| Dickinson, SO | 1 |
| Eissa, S | 1 |
| Eskow Jaunarajs, KL | 1 |
| Le Ber, I | 1 |
| Dubois, B | 1 |
1 review available for fluoxetine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
[Frontotemporal dementia].
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alzheimer Disease; Amyotrophic Lateral Sclerosis | 2007 |
5 other studies available for fluoxetine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity.
Topics: Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Depression; Drug Therapy, Comb | 2022 |
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa | 2015 |
Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress.
Topics: Animals; Enzyme Activation; Female; Fluoxetine; Lipopolysaccharides; Microglia; NADPH Oxidases; Nerv | 2010 |
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Arip | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskin | 2012 |